• J Y Pierga, E Mouret, V Diéras, V Laurence, P Beuzeboc, T Dorval, T Palangié, M Jouve, A Vincent-Salomon, S Scholl, J M Extra, B Asselain, and P Pouillart.
• Medical Oncology Department, Institut Curie, 26 Rue d'Ulm, Paris Cedex 05, 75248, France.
• Br. J. Cancer. 2000 Dec 1; 83 (11): 1480-7.

AbstractNeoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess the prognostic value of persistent node involvement after neoadjuvant chemotherapy. A total of 488 patients with T2-T3, N0-N1 breast cancer treated by neoadjuvant chemotherapy followed by tumour excision and axillary lymph-node dissection between 1981 and 1992 were selected from the Institut Curie database. Median follow-up was 7 years. Overall objective response rate before local treatment was 52% and breast tumour size was reduced in 83% of patients. No pathologic nodal involvement was observed in 46. 5% of patients. Patients with > or = eight positive nodes had a very poor median disease-free survival of only 20 months. Their 10-year disease-free survival rate was 7%, while the 10-year disease-free survival rate for patients with no node involvement was 64%. Median survival for patients with > or = eight nodes positive was 48 months and the 10-year survival rate was 26% (P < 0.0001). On multivariate analysis, outcome was strongly correlated with pathological nodal status, tumour grade, hormonal receptor status and clinical response of the tumour. In conclusion, patients with extensive nodal involvement after neoadjuvant chemotherapy have a very poor outcome. Second-line treatment should be considered in this population.Copyright 2000 Cancer Research Campaign.

40 keywords...

hide…